MX2008007287A - Metodos y composiciones para expandir celulas reguladoras t. - Google Patents
Metodos y composiciones para expandir celulas reguladoras t.Info
- Publication number
- MX2008007287A MX2008007287A MX2008007287A MX2008007287A MX2008007287A MX 2008007287 A MX2008007287 A MX 2008007287A MX 2008007287 A MX2008007287 A MX 2008007287A MX 2008007287 A MX2008007287 A MX 2008007287A MX 2008007287 A MX2008007287 A MX 2008007287A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- cells
- vivo
- expanding
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 210000003289 regulatory T cell Anatomy 0.000 title abstract 3
- 206010052779 Transplant rejections Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010068051 Chimerism Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 230000000961 alloantigen Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 abstract 1
- 210000002798 bone marrow cell Anatomy 0.000 abstract 1
- 230000011712 cell development Effects 0.000 abstract 1
- 230000000139 costimulatory effect Effects 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464496—Fusion proteins originating from gene translocation in cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
Abstract
La presente invención se refiere a métodos y composiciones para expandir células Treg ex vivo in vivo, usando uno o más conjugados que comprenden una porción coestimuladora que estimula al menos una de las tres señales involucradas en el desarrollo de células Treg y/o usar células dendríticas pulsadas con antígenos y modificadas para exhibir el TGF-?, o células troncales hemotopoyéticas o células de la médula ósea modificadas para exhibir el TGF-?. Los métodos y composiciones son empleados por ejemplo, en el tratamiento y prevención de enfermedades autoinmunes, que incluye diabetes Tipo 1 y en la prevención de rechazo a injerto extraño, así como también, para establecer quimerismo combinado, inducir tolerancia a autoantígenos, aloantígenos o xenoantígenos, generación de células beta, prevención de rechazo al injerto extraño y tratamiento de un trastorno hematopoyético genéticamente heredado.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74817705P | 2005-12-08 | 2005-12-08 | |
US75839106P | 2006-01-12 | 2006-01-12 | |
US79964206P | 2006-05-12 | 2006-05-12 | |
US79964306P | 2006-05-12 | 2006-05-12 | |
PCT/US2006/046664 WO2007067683A2 (en) | 2005-12-08 | 2006-12-07 | Methods and compositions for expanding t regulatory cells |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2008007287A true MX2008007287A (es) | 2008-10-27 |
Family
ID=38123486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2008007287A MX2008007287A (es) | 2005-12-08 | 2006-12-07 | Metodos y composiciones para expandir celulas reguladoras t. |
Country Status (8)
Country | Link |
---|---|
US (2) | US7745215B2 (es) |
EP (1) | EP1973573B1 (es) |
JP (1) | JP2009521409A (es) |
KR (1) | KR20080090413A (es) |
AU (1) | AU2006321890A1 (es) |
CA (1) | CA2633161A1 (es) |
MX (1) | MX2008007287A (es) |
WO (1) | WO2007067683A2 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002216763B2 (en) | 2000-06-30 | 2007-03-01 | University Of Louisville Research Foundation, Inc. | Alteration of cell membrane |
SI1907000T2 (sl) | 2005-06-08 | 2020-07-31 | Dana-Farber Cancer Institute | Postopki in sestavki za zdravljenje persistentne HIV infekcije z inhibicijo programiranih celični smrtnih 1 (PD-1) poti |
MX2008007287A (es) * | 2005-12-08 | 2008-10-27 | Univ Louisville Res Found | Metodos y composiciones para expandir celulas reguladoras t. |
EP1963371A2 (en) | 2005-12-08 | 2008-09-03 | Medarex Inc. | Human monoclonal antibodies to o8e |
AU2006321888A1 (en) * | 2005-12-08 | 2007-06-14 | University Of Louisville Research Foundation, Inc. | Immunostimulatory compositions and methods |
EP2010906B1 (de) * | 2006-03-24 | 2014-06-11 | Miltenyi Biotec GmbH | Verwendung des 4-1bb rezeptors zur identifizierung und/oder separation aktivierter regulatorischer th-zellen (treg) |
EP2133365B1 (en) * | 2006-12-27 | 2017-05-17 | Emory University | Compositions and methods for the treatment of infections and tumors |
US20110076258A1 (en) * | 2008-03-03 | 2011-03-31 | Converge Biotech Inc. | Methods of modulating t cell- dependent immune responses |
US8658159B2 (en) * | 2008-06-30 | 2014-02-25 | Versitech Limited | Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale |
EP2342356A4 (en) | 2008-09-29 | 2012-11-21 | Univ Ben Gurion | AMYLOID BETA PEPTIDASES AND METHOD OF USE THEREOF |
MX2011005691A (es) | 2008-11-28 | 2011-07-20 | Univ Emory | Metodos para el tratamiento de infecciones y tumores. |
JP5980508B2 (ja) | 2009-03-11 | 2016-08-31 | プロメディオール, インコーポレイテッド | 自己免疫障害に対する処置方法 |
JP5797565B2 (ja) | 2009-03-11 | 2015-10-21 | プロメディオール, インコーポレイテッド | 過敏性障害(hypersensitive disorder)に対する処置および診断方法 |
WO2010132697A2 (en) * | 2009-05-13 | 2010-11-18 | Genzyme Corporation | Methods and compositions for treatment |
WO2011130249A2 (en) * | 2010-04-13 | 2011-10-20 | Immunovative Therapies, Ltd. | Methods and compositions for inhibition of treg cells |
US9624469B2 (en) | 2010-07-22 | 2017-04-18 | Cellect Biotherapeutics Ltd. | Regulatory immune cells with enhanced targeted cell death effect |
WO2012096376A1 (ja) * | 2011-01-14 | 2012-07-19 | タカラバイオ株式会社 | 制御性t細胞の製造方法 |
WO2012109203A1 (en) * | 2011-02-10 | 2012-08-16 | University Of Louisville Research Foundation, Inc. | Adjuvant compositions with 4-ibbl |
EA027410B1 (ru) | 2011-04-29 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Наноносители, вызывающие иммунную толерантность, для снижения ответной реакции цитотоксических t-лимфоцитов |
CA2847555A1 (en) | 2011-09-08 | 2013-03-14 | University Of Florida Research Foundation, Inc. | Materials and methods for modulating immune responses |
CN105338968A (zh) | 2013-05-03 | 2016-02-17 | 西莱克塔生物科技公司 | 降低或预防响应于非变应原性抗原的过敏反应的致耐受性合成纳米载体 |
CN105408473B9 (zh) | 2013-05-14 | 2021-09-17 | 得克萨斯州大学系统董事会 | 工程化嵌合抗原受体(car)t细胞的人应用 |
US10092597B2 (en) | 2014-01-14 | 2018-10-09 | The University Of Hong Kong | Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice |
CA2957737A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses |
EP3237906B8 (en) * | 2014-12-23 | 2020-10-28 | Bluelight Therapeutics, Inc. | Attachment of proteins to interfaces for use in nonlinear optical detection |
US11129882B2 (en) | 2015-10-30 | 2021-09-28 | University Of Copenhagen | Virus like particle with efficient epitope display |
WO2018109667A1 (en) | 2016-12-15 | 2018-06-21 | Nestec Sa | Compositions and methods that modulate white blood cells or neutrophils in a companion animal |
BR112019018748A2 (pt) | 2017-03-11 | 2020-04-07 | Selecta Biosciences Inc | métodos e composições relacionados ao tratamento combinado com anti-inflamatórios e nanocarreadores sintéticos compreendendo um imunossupressor |
WO2020204601A1 (ko) * | 2019-04-05 | 2020-10-08 | 한국세라믹기술원 | Csq-태그를 이용한 단백질의 발현 및 정제 방법 |
JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | 1型糖尿病を予防するための方法および組成物 |
IL291909A (en) | 2019-11-20 | 2022-06-01 | Gi Cell Inc | The composition of T regulatory cell culture and its use |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6232088B1 (en) * | 1995-02-08 | 2001-05-15 | Phairson Medical, Inc. | Treatment and prevention of immune rejection reactions |
HUP0201222A3 (en) | 1999-05-06 | 2004-07-28 | Genetics Inst Llc Delaware All | Use of soluble constimulatory molecules to enhance immune responses |
US20040214783A1 (en) * | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
AU2002216763B2 (en) | 2000-06-30 | 2007-03-01 | University Of Louisville Research Foundation, Inc. | Alteration of cell membrane |
WO2002067863A2 (en) * | 2001-02-22 | 2002-09-06 | The Scepens Eye Research Institute, Inc. | Tolerogenic antigen presenting cells and in treating immune-inflammatory conditions |
AU2003248255A1 (en) * | 2003-07-09 | 2005-01-28 | Oncorex, Inc. | Dendritic cell infiltrativity activating composition and immune activator |
EP1736482A1 (en) | 2005-06-20 | 2006-12-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Recombinant trimeric 4-1BBL |
MX2008007287A (es) * | 2005-12-08 | 2008-10-27 | Univ Louisville Res Found | Metodos y composiciones para expandir celulas reguladoras t. |
AU2006321888A1 (en) * | 2005-12-08 | 2007-06-14 | University Of Louisville Research Foundation, Inc. | Immunostimulatory compositions and methods |
-
2006
- 2006-12-07 MX MX2008007287A patent/MX2008007287A/es not_active Application Discontinuation
- 2006-12-07 EP EP06848527.5A patent/EP1973573B1/en not_active Not-in-force
- 2006-12-07 CA CA002633161A patent/CA2633161A1/en not_active Abandoned
- 2006-12-07 WO PCT/US2006/046664 patent/WO2007067683A2/en active Application Filing
- 2006-12-07 KR KR1020087016532A patent/KR20080090413A/ko not_active Application Discontinuation
- 2006-12-07 JP JP2008544502A patent/JP2009521409A/ja active Pending
- 2006-12-07 US US11/635,087 patent/US7745215B2/en not_active Expired - Fee Related
- 2006-12-07 AU AU2006321890A patent/AU2006321890A1/en not_active Abandoned
-
2010
- 2010-06-25 US US12/823,430 patent/US20110052529A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2006321890A1 (en) | 2007-06-14 |
KR20080090413A (ko) | 2008-10-08 |
CA2633161A1 (en) | 2007-06-14 |
WO2007067683A2 (en) | 2007-06-14 |
US20070172947A1 (en) | 2007-07-26 |
US7745215B2 (en) | 2010-06-29 |
WO2007067683A3 (en) | 2008-04-03 |
EP1973573A2 (en) | 2008-10-01 |
JP2009521409A (ja) | 2009-06-04 |
US20110052529A1 (en) | 2011-03-03 |
EP1973573B1 (en) | 2013-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2008007287A (es) | Metodos y composiciones para expandir celulas reguladoras t. | |
Ryan et al. | Chondrogenic differentiation increases antidonor immune response to allogeneic mesenchymal stem cell transplantation | |
Mackenzie et al. | Human mesenchymal stem cells persist, demonstrate site-specific multipotential differentiation, and are present in sites of wound healing and tissue regeneration after transplantation into fetal sheep | |
Brauer et al. | Modern human origins backdated | |
GB2453068A (en) | Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells | |
Leonard et al. | Induction of tolerance of vascularized composite allografts | |
EA201100663A1 (ru) | Соединения, которые увеличивают количество гематопоэтических стволовых клеток | |
DE69832402D1 (de) | Erzeugung von hämatopoietischen zellen aus multipotenten neuronalen stammzellen | |
WO2007084775A3 (en) | Compositions and methods for modulation of suppressor t cell activation | |
WO2001007568A3 (en) | Muscle cells and their use in cardiac repair | |
Ramirez et al. | A novel rat full‐thickness hemi‐abdominal wall/hindlimb osteomyocutaneous combined flap: Influence of allograft mass and vascularized bone marrow content on vascularized composite allograft survival | |
Shelikhova et al. | αβ T cell-depleted haploidentical hematopoietic stem cell transplantation without antithymocyte globulin in children with chemorefractory acute myelogenous leukemia | |
Marmont | Will hematopoietic stem cell transplantation cure human autoimmune diseases? | |
IL161832A0 (en) | Pharmaceutical composition for inducing an immune response in a human or animal | |
MX2019002288A (es) | Suspensión celular para usarse en el tratamiento de la arteriopatía periférica de las extremidades inferiores. | |
Dor et al. | Galα1, 3Gal expression on porcine pancreatic islets, testis, spleen, and thymus | |
WO2003012060A3 (en) | Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd | |
EP0700297A4 (en) | SUBSTITUTION TOLEROGENESIS FOR THE DEVELOPMENT OF XENOGRAFT TOLERANCE | |
WO2003080798A3 (en) | Muscle cells and their use in cardiac repair | |
SG155212A1 (en) | Methods for identifying factors for differentiating definitive endoderm | |
Leonard et al. | Allogeneic bone marrow transplant from MRL/MpJ super-healer mice does not improve articular cartilage repair in the C57Bl/6 strain | |
GB2435598A (en) | Methods for supporting and producing human cells and tissues in non-human mammal hosts | |
Kagami | The potential use of cell‐based therapies in the treatment of oral diseases | |
DK1224264T3 (da) | Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponser | |
Fu et al. | Successful transplantation of kidney allografts in sensitized rats after syngeneic hematopoietic stem cell transplantation and fludarabine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |